CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Episodes 385-400 of 403
Charu Aggarwal, MD, MPH
Patrick Forde, M.B.B.Ch.
- MinuteCE®
What Are the Data Supporting First Line C5 Inhibitor Treatment of PNH?
0.75 program creditsCatherine Broome, MD
- MinuteCE®
Reconsidering First Line PNH Treatment: Is There a Standard of Care?
0.75 credits 6 episodesCatherine Broome, MD
Carlos M. de Castro, MD
Catherine Broome, MD
Catherine Broome, MD
- MinuteCE®
What Is the Impact of First line PNH Treatment Choice on Risk of Thrombosis
0.75 program creditsCarlos M. de Castro, MD
Carlos M. de Castro, MD
- MinuteCE®
What Are the Data Supporting First Line C3 Inhibitor Treatment of PNH?
0.75 program creditsCarlos M. de Castro, MD
Gregory J. Fermann, MD
Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
W. Brian Gibler, MD, FACEP, FACC, FAHA
Gregory J. Fermann, MD
Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
Natalie Kreitzer, MD, MS
Gregory J. Fermann, MD
- MinuteCE®
Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
1.50 program creditsNatalie Kreitzer, MD, MS
W. Brian Gibler, MD, FACEP, FACC, FAHA
Gregory J. Fermann, MD
Natalie Kreitzer, MD, MS
Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP